ETON's Quality Score fell 1 point on Tue, Nov 10, to 20. Charles J. Casamento (Director) sold $2M on Nov 10, filed Nov 10, and 4 more filings.
Follow ETON's news. Pro members can get an alert when Eton Pharmaceutcials files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 5.0% today, while its biotech peers are down 1.4%; no story names it yet.
Rose 43% since Nov 5
Up 43% from Nov 5 to Nov 10.
| Outperforming | Up 299% this year vs the S&P's +10% |
| Latest filing | 8-K, Nov 5 |
TodayNo story names it yet.
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
After its last 4 reports it closed +18.1% on average, higher 4 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
Chief Business Officer David Krempa sold 4,166 shares on Oct 6. 6 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Exceptionalfor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ETON scores 20 today, against a median of 10 over its last 20 recorded sessions.
ETON is #3 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Expected to report Thu Mar 25, after the close (in 135 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $57.9M, 158% more than a year ago; a profit of $1.06 a share, from a loss of $0.07.
“Total net revenue for the third quarter of 2026 was $57.9 million compared to $22.5 million in the prior year period, an increase of 158%, driven by the addition of revenue from HEMANGEOL, as well as year-over-year growth across the portfolio, in particular from INCRELEX, ALKINDI SPRINKLE, GALZIN, KHINDIVI, DESMODA, and Carglumic Acid.”
ETON's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | more than $175 million |
“Gross profit for the third quarter of 2026 was $44.3 million compared with $7.9 million in the prior year period, an increase of 464%, primarily due to increased product sales and a favorable change in product mix.”
From its results filing (SEC filing · Nov 5)
Free cash flow grew 29% a year over 3 years, fiscal 2022 to 2025.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +24.3% | +19.8% | not yet |
| Aug 13, 2026 | +34.6% | +44.3% | +46.8% |
| May 14, 2026 | -3.1% | +1.0% | +16.8% |
Sales grew in four of the last six years, to $80M in 2025. It lost money in each of the seven years.
RSI 72.5, MACD above signal, above both averages. Not scored.
6 insiders sold $30.8M across 29 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
“We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.”
ETON scores 20 today, which Breakaway calls Exceptional. It is #3 of 281 in Biotech by Quality Score, with 9 of 14 chart checks firing. Up 43% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ETON scores 20 today, which Breakaway calls Exceptional (20 or more). That is #3 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ETON's 20.
6 insiders sold $30.8M across 29 filings in the last 6 months. No open-market buys on record. The newest is Charles J. Casamento, Director, who sold $2.3M on Nov 10. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.